[HTML][HTML] That escalated quickly: remdesivir's place in therapy for COVID-19
MR Davis, EK McCreary, JM Pogue - Infectious diseases and therapy, 2020 - Springer
MR Davis, EK McCreary, JM Pogue
Infectious diseases and therapy, 2020•SpringerRemdesivir is a nucleoside antiviral recently studied in several randomized trials for
treatment of COVID-19. The available observational and prospective data are conflicting,
requiring clinicians to critically evaluate and reconcile results to determine patient
populations that may optimally benefit from remdesivir therapy, especially while drug supply
is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with
COVID-19 from January 1, 2020, through May 31, 2020.
treatment of COVID-19. The available observational and prospective data are conflicting,
requiring clinicians to critically evaluate and reconcile results to determine patient
populations that may optimally benefit from remdesivir therapy, especially while drug supply
is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with
COVID-19 from January 1, 2020, through May 31, 2020.
Abstract
Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.
Springer